AlphAIalphai — Financial news for AI agents
ocbj.comJUL 72 min read$RXST

RxSight Announces Preliminary Q2 Results

RxSight Inc. (Nasdaq: RXST) reported preliminary Q2 results and updated 2026 guidance. It expects Q2 revenue of $32M–$34M and full-year sales of $110M–$120M, down from $120M–$135M. Final Q2 results are due after market close Aug. 5. Shares fell 6.3% to $5.25.

Original reporting
ocbj.com
Published Jul 7, 2026, 9:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 7, 2026, 9:57 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
RxSight Announces Preliminary Q2 Results — source image
Source · ocbj.com
Decision brief

The 30-second read

$RXSTBearishMed
01

Why it matters

The key tradable inputs are the preliminary Q2 revenue range, the reduced full-year sales forecast, and the scheduled Aug. 5 after-hours earnings release that can confirm or revise expectations.

02

Market read

RXST’s guidance reduction is the dominant near-term driver, with the Aug. 5 earnings date setting a clear event window for re-pricing.

03

What to watch

The article provides ranges but no margin, cash flow, or order backlog details; traders may need the Aug. 5 release to judge whether the guidance reduction is temporary.

Relevance 7/10Novelty 6/10Timing: Ahead of after-hours Q2 results on Aug. 5.

Background

RxSight is a cataract lens maker; the company provided preliminary Q2 figures and updated 2026 sales guidance, plus a new Alcon collaboration.

Company-level read

Ticker impact

$RXSTBearishMedium confidence
Context

RxSight issued preliminary Q2 revenue of $32M–$34M and cut full-year sales guidance to $110M–$120M.

Expected impact

Likely continued downside pressure into the Aug. 5 print unless results/forward commentary offset the guidance reduction.

Evidence & confidence

The article discloses both preliminary quarterly revenue and a reduced full-year sales range, which typically drives estimate revisions and sentiment.

Market effects

Sector

Signals demand/visibility pressure in cataract lens/ophthalmic device revenue expectations, potentially affecting read-across sentiment for medtech peers.

Regional

Limited; primarily a US small-cap medtech name with Nasdaq liquidity.

Global

Low; collaboration with Alcon is notable but not quantified in the article.

Counterpoint

What could challenge this read

The guidance cut may reflect timing/phasing rather than demand deterioration, and the Alcon collaboration could support longer-term product differentiation.

Key entities

  • company
    RxSight Inc.

    Preliminary Q2 revenue guidance and reduced 2026 sales forecast; will report Q2 results after the market closes on Aug. 5.

  • company
    Alcon

    Collaboration partner for technology to customize patients’ vision after cataract surgery.

Read at source← All news

Related articles

AUG 5
$RXSTMedAI 8/10

RxSight, Inc. (RXST): Results of Operations and Financial Condition

RxSight, Inc. (RXST) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 rxst-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 RXSIGHT, INC. REPORTS SECOND QUARTER 2026 RESULTS AND PROVIDES UPDATE ON 2026 OUTLOOK Aliso Viejo, Calif. – August 5, 2026 – RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter ended June 30, 2026, a

SEC EDGAR 8-K6 min
AUG 1
$RXSTMed

RxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer

RxSight, Inc. (NASDAQ: RXST) announced a leadership transition effective July 20, 2026. Aziz Mottiwala will become President and CEO, succeeding Ron Kurtz, M.D., who will remain Chief Medical Officer. Kurtz will also resign from the board, with Mottiwala appointed in his place. The company cited commercial and clinical continuity around its light adjustable lens technology.

hrtoday.in3 min
JUL 20
$RXSTMed

RxSight Lands Tarsus Commercial Leader as CEO

RxSight (Nasdaq: RXST) appointed Aziz Mottiwala as CEO on July 15, replacing Dr. Ron Kurtz, who becomes chief medical officer. Mottiwala previously served as Tarsus Pharmaceuticals’ chief commercial officer. RXST shares rose 7.2% to $5.63 after the news. The article cites RXST’s forecast cuts and a Bank of America price target cut to $6.50, plus an Alcon partnership with $60 million upfront and up to $140 million in milestones.

ocbj.com6 min
JUL 11
$RXSTMedAI 8/10

RxSight Q2 Sales Sink 20% as Alcon Deal Bolsters 2026 Outlook

RxSight (NASDAQ:RXST) reported Q2 sales of 11 Light Delivery Devices (LDDs) and one LDD rental, lowering sales 20% and leaving an installed base of 1,166 units. Cash, cash equivalents and short-term investments were about $209M. It revised 2026 revenue to $140M-$160M, including $110M-$120M RxSight sales and $30M-$40M Alcon collaboration revenue, and raised gross margin outlook to 73%-75%.

yahoo.com4 min
JUL 7
$ALCMed

Alcon, RxSight Collaborate To Develop Adjustable PCIOLs; RxSight To Get Up To $200 Mln

Alcon (ALC) and RxSight (RXST) announced a non-exclusive collaboration to develop adjustable presbyopia-correcting intraocular lenses (PCIOLs). RxSight will get a $60M upfront payment and up to $140M more tied to development/regulatory milestones. Alcon will lead commercialization; RxSight will handle development/manufacturing and earn royalties. Alcon shares rose to $68.42; RxSight fell.

rttnews.com2 min